Corxel Pharmaceuticals closed a $287 million Series D1 round to accelerate global development of CX11, an oral small‑molecule GLP‑1 receptor agonist for obesity and type 2 diabetes. Investors included RTW Investments, Hengdian Group Capital, TCGX Crossover, SR One, RA Capital and HBM Healthcare. CEO Sandy Mou said the financing propels Corxel to a new growth phase. Corxel reported Phase II data showing ~9.4–9.7% mean weight loss at 16 weeks for CX11. The company is running Phase II in the US and Phase III in China; the funding will support late‑stage development and global expansion of an oral GLP‑1 alternative to injectables.